Expression of Her-2/neu on Acute Lymphoblastic Leukemias
Her-2/neu is a tumor-associated antigen that is expressed on several adenocarcinomas and correlates with poor prognosis. In a previous study (H. J. Bühring et al. , Blood, 86: 1916–1923, 1995), it has been demonstrated that Her-2/neu expression can be detected on blast cells from patients with hemat...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2003-08, Vol.9 (9), p.3448 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 3448 |
| container_title | Clinical cancer research |
| container_volume | 9 |
| creator | Martin R. Müller Frank Grünebach Katrin Kayser Wichard Vogel Alessio Nencioni Wolfram Brugger Lothar Kanz Peter Brossart |
| description | Her-2/neu is a tumor-associated antigen that is expressed on several adenocarcinomas and correlates with poor prognosis. In
a previous study (H. J. Bühring et al. , Blood, 86: 1916–1923, 1995), it has been demonstrated that Her-2/neu expression can be detected on blast cells from patients with hematological
malignancies including acute lymphoblastic leukemia (ALL). Here, we show that Her-2/neu-specific CTLs induced in vitro using peptide-pulsed dendritic cells efficiently lyse primary ALL blasts constitutively expressing both Her-2/neu and human
leukocyte antigen A2 in an antigen-specific and MHC-restricted manner. Furthermore, we analyzed the feasibility of this approach
in an autologous setting and induced Her-2/neu-specific CTLs using dendritic cells generated from peripheral blood mononuclear
cells from an ALL patient that were pulsed with peptides or transfected with in vitro -transcribed Her-2/neu mRNA. Our data demonstrate that Her-2/neu could be used as a potential target for the application of
Her-2/neu-directed treatment strategies in ALL including vaccination approaches. |
| format | Article |
| fullrecord | <record><control><sourceid>highwire</sourceid><recordid>TN_cdi_highwire_cancerresearch_9_9_3448</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9_9_3448</sourcerecordid><originalsourceid>FETCH-highwire_cancerresearch_9_9_34483</originalsourceid><addsrcrecordid>eNqNjMkKwjAYhIMoti7vkJunYLZuR5FKDz16LzH8NdFuJC3q29uDDyBzmG_gYxYoZFGUEMHjaDkzTVJCpeAB2nj_oJRJRuUaBYxnMWUiDlGavwcH3tu-w32NC3CEHzuY8LxPehoBl592MP2tUX60GpcwPaG1yu_QqlaNh_2vt-hwya_nghh7Ny_roNKq0-Dmc1BOmyqbI6RMxf_mFzExPK0</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Expression of Her-2/neu on Acute Lymphoblastic Leukemias</title><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Martin R. Müller ; Frank Grünebach ; Katrin Kayser ; Wichard Vogel ; Alessio Nencioni ; Wolfram Brugger ; Lothar Kanz ; Peter Brossart</creator><creatorcontrib>Martin R. Müller ; Frank Grünebach ; Katrin Kayser ; Wichard Vogel ; Alessio Nencioni ; Wolfram Brugger ; Lothar Kanz ; Peter Brossart</creatorcontrib><description>Her-2/neu is a tumor-associated antigen that is expressed on several adenocarcinomas and correlates with poor prognosis. In
a previous study (H. J. Bühring et al. , Blood, 86: 1916–1923, 1995), it has been demonstrated that Her-2/neu expression can be detected on blast cells from patients with hematological
malignancies including acute lymphoblastic leukemia (ALL). Here, we show that Her-2/neu-specific CTLs induced in vitro using peptide-pulsed dendritic cells efficiently lyse primary ALL blasts constitutively expressing both Her-2/neu and human
leukocyte antigen A2 in an antigen-specific and MHC-restricted manner. Furthermore, we analyzed the feasibility of this approach
in an autologous setting and induced Her-2/neu-specific CTLs using dendritic cells generated from peripheral blood mononuclear
cells from an ALL patient that were pulsed with peptides or transfected with in vitro -transcribed Her-2/neu mRNA. Our data demonstrate that Her-2/neu could be used as a potential target for the application of
Her-2/neu-directed treatment strategies in ALL including vaccination approaches.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>PMID: 12960136</identifier><language>eng</language><publisher>American Association for Cancer Research</publisher><ispartof>Clinical cancer research, 2003-08, Vol.9 (9), p.3448</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Martin R. Müller</creatorcontrib><creatorcontrib>Frank Grünebach</creatorcontrib><creatorcontrib>Katrin Kayser</creatorcontrib><creatorcontrib>Wichard Vogel</creatorcontrib><creatorcontrib>Alessio Nencioni</creatorcontrib><creatorcontrib>Wolfram Brugger</creatorcontrib><creatorcontrib>Lothar Kanz</creatorcontrib><creatorcontrib>Peter Brossart</creatorcontrib><title>Expression of Her-2/neu on Acute Lymphoblastic Leukemias</title><title>Clinical cancer research</title><description>Her-2/neu is a tumor-associated antigen that is expressed on several adenocarcinomas and correlates with poor prognosis. In
a previous study (H. J. Bühring et al. , Blood, 86: 1916–1923, 1995), it has been demonstrated that Her-2/neu expression can be detected on blast cells from patients with hematological
malignancies including acute lymphoblastic leukemia (ALL). Here, we show that Her-2/neu-specific CTLs induced in vitro using peptide-pulsed dendritic cells efficiently lyse primary ALL blasts constitutively expressing both Her-2/neu and human
leukocyte antigen A2 in an antigen-specific and MHC-restricted manner. Furthermore, we analyzed the feasibility of this approach
in an autologous setting and induced Her-2/neu-specific CTLs using dendritic cells generated from peripheral blood mononuclear
cells from an ALL patient that were pulsed with peptides or transfected with in vitro -transcribed Her-2/neu mRNA. Our data demonstrate that Her-2/neu could be used as a potential target for the application of
Her-2/neu-directed treatment strategies in ALL including vaccination approaches.</description><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqNjMkKwjAYhIMoti7vkJunYLZuR5FKDz16LzH8NdFuJC3q29uDDyBzmG_gYxYoZFGUEMHjaDkzTVJCpeAB2nj_oJRJRuUaBYxnMWUiDlGavwcH3tu-w32NC3CEHzuY8LxPehoBl592MP2tUX60GpcwPaG1yu_QqlaNh_2vt-hwya_nghh7Ny_roNKq0-Dmc1BOmyqbI6RMxf_mFzExPK0</recordid><startdate>20030801</startdate><enddate>20030801</enddate><creator>Martin R. Müller</creator><creator>Frank Grünebach</creator><creator>Katrin Kayser</creator><creator>Wichard Vogel</creator><creator>Alessio Nencioni</creator><creator>Wolfram Brugger</creator><creator>Lothar Kanz</creator><creator>Peter Brossart</creator><general>American Association for Cancer Research</general><scope/></search><sort><creationdate>20030801</creationdate><title>Expression of Her-2/neu on Acute Lymphoblastic Leukemias</title><author>Martin R. Müller ; Frank Grünebach ; Katrin Kayser ; Wichard Vogel ; Alessio Nencioni ; Wolfram Brugger ; Lothar Kanz ; Peter Brossart</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-highwire_cancerresearch_9_9_34483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martin R. Müller</creatorcontrib><creatorcontrib>Frank Grünebach</creatorcontrib><creatorcontrib>Katrin Kayser</creatorcontrib><creatorcontrib>Wichard Vogel</creatorcontrib><creatorcontrib>Alessio Nencioni</creatorcontrib><creatorcontrib>Wolfram Brugger</creatorcontrib><creatorcontrib>Lothar Kanz</creatorcontrib><creatorcontrib>Peter Brossart</creatorcontrib><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martin R. Müller</au><au>Frank Grünebach</au><au>Katrin Kayser</au><au>Wichard Vogel</au><au>Alessio Nencioni</au><au>Wolfram Brugger</au><au>Lothar Kanz</au><au>Peter Brossart</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of Her-2/neu on Acute Lymphoblastic Leukemias</atitle><jtitle>Clinical cancer research</jtitle><date>2003-08-01</date><risdate>2003</risdate><volume>9</volume><issue>9</issue><spage>3448</spage><pages>3448-</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Her-2/neu is a tumor-associated antigen that is expressed on several adenocarcinomas and correlates with poor prognosis. In
a previous study (H. J. Bühring et al. , Blood, 86: 1916–1923, 1995), it has been demonstrated that Her-2/neu expression can be detected on blast cells from patients with hematological
malignancies including acute lymphoblastic leukemia (ALL). Here, we show that Her-2/neu-specific CTLs induced in vitro using peptide-pulsed dendritic cells efficiently lyse primary ALL blasts constitutively expressing both Her-2/neu and human
leukocyte antigen A2 in an antigen-specific and MHC-restricted manner. Furthermore, we analyzed the feasibility of this approach
in an autologous setting and induced Her-2/neu-specific CTLs using dendritic cells generated from peripheral blood mononuclear
cells from an ALL patient that were pulsed with peptides or transfected with in vitro -transcribed Her-2/neu mRNA. Our data demonstrate that Her-2/neu could be used as a potential target for the application of
Her-2/neu-directed treatment strategies in ALL including vaccination approaches.</abstract><pub>American Association for Cancer Research</pub><pmid>12960136</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2003-08, Vol.9 (9), p.3448 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_highwire_cancerresearch_9_9_3448 |
| source | American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Expression of Her-2/neu on Acute Lymphoblastic Leukemias |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A30%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-highwire&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20Her-2/neu%20on%20Acute%20Lymphoblastic%20Leukemias&rft.jtitle=Clinical%20cancer%20research&rft.au=Martin%20R.%20M%C3%BCller&rft.date=2003-08-01&rft.volume=9&rft.issue=9&rft.spage=3448&rft.pages=3448-&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/&rft_dat=%3Chighwire%3E9_9_3448%3C/highwire%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12960136&rfr_iscdi=true |